Araris Biotech AG kicks-off with CHF2.5m seed financing
Zurich-based ADC maker Araris Biotech AG announced the closing of an oversubscribed seed financing round of CHF2.5m with Redalpine, Schroder Adveq and VI Partners contibuting.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1255 entries already.
Entries by Thomas Gabrielczyk
Swedish researchers find new pain organ
/in News/by Thomas GabrielczykResearchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts.
Researchers unravel potential cancer target
/in News/by Thomas GabrielczykBritish researchers have found out what’s going wrong with chromosome segregation in some cancers.
Pharming licenses orphan drug from Novartis
/in News/by Thomas GabrielczykPharming NV has paid 17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS
New stem cell population may help repair teeth
/in News/by Thomas GabrielczykResearchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future.
Bayer bags iPSC specialist BlueRock Therapeutics
/in News/by Thomas GabrielczykBayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.
Liquid biopsy identifies residual breast cancer
/in News/by Thomas GabrielczykUsing a platform tailored to patients specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.
Google maps for tumours and organs
/in News/by Thomas GabrielczykGerman researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy.
Transgenes licenced oncolytic virus fails in Phase III
/in News/by Thomas GabrielczykSillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be […]
Alizé Pharma 3 bags largest EU financing so far
/in News/by Thomas GabrielczykVenture Captital specialist LSP led a 67m Series A financing in peptide developer Alizé Pharma 3.